Fertility drug use and mammographic breast density in a mammography screening cohort of premenopausal women

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 11, 2008, Pages 3128-3133

  Sprague, Brian L ^a,b   Trentham Dietz, Amy ^a,b   Terry, Mary Beth ^c   Nichols, Hazel B ^b   Bersch, Andrew J ^b   Buist, Diana S M ^d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c Group Health Center for Health Studies ^*  (United States)

^d CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERTILITY PROMOTING AGENT; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BODY FAT; BODY MASS; BREAST CANCER; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; EDUCATIONAL STATUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PHARMACY; PREMENOPAUSE; PRIORITY JOURNAL; RACE;

ADULT; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; FEMALE; FERTILITY AGENTS, FEMALE; HUMANS; INFERTILITY, FEMALE; LOGISTIC MODELS; MAMMOGRAPHY; MIDDLE AGED; PREMENOPAUSE; RISK FACTORS; WASHINGTON;

EID: 55849093939     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0503     Document Type: Article

References (35)

1. Stephen EH, Chandra A. Updated projections of infertility in the United States: 1995-2025. Fertil Steril 1998;70:30-4.
2. Wysowski DK. Use of fertility drugs in the United States, 1973 through 1991. Fertil Steril 1993;60:1096-8.
3. Thonneau P, Marchand S, Tallec A, et al. Incidence and main causes of infertility in a resident population (1,850,000) of three French regions (1988-1989). Hum Reprod 1991;6:811-6.
4. Miller JH, Weinberg RK, Canino NL, Klein NA, Soules MR. The pattern of infertility diagnoses in women of advanced reproductive age. Am J Obstet Gynecol 1999;181:952-7.
5. Sovino H, Sir-Petermann T, Devoto L. Clomiphene citrate and ovulation induction. Reprod Biomed Online 2002;4:303-10.
6. Derman SG, Adashi EY. Adverse effects of fertility drugs. Drug Saf 1994;11:408-21.
7. MacLachlan V, Besanko M, O'Shea F, et al. A controlled study of luteinizing hormone-releasing hormone agonist (buserelin) for the induction of folliculogenesis before in vitro fertilization. N Engl J Med 1989;320:1233-7.
8. Hankinson SE, Colditz GA, Willett WC. Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res 2004;6:213-8.
9. Clavel-Chapelon F. Cumulative number of menstrual cycles and breast cancer risk: results from the E3N cohort study of French women. Cancer Causes Control 2002;13:831-8.
10. Garland M, Hunter DJ, Colditz GA, et al. Menstrual cycle characteristics and history of ovulatory infertility in relation to breast cancer risk in a large cohort of US women. Am J Epidemiol 1998;147:636-43.
11. Brinton L. Long-term effects of ovulation-stimulating drugs on cancer risk. Reprod Biomed Online 2007;15:38-44.
12. Burkman RT, Tang MT, Malone KE, et al. Infertility drugs and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women's Contraceptive and Reproductive Experiences Study. Fertil Steril 2003;79:844-51.
13. Lerner-Geva L, Keinan-Boker L, Blumstein T, et al. Infertility, ovulation induction treatments and the incidence of breast cancer - a historical prospective cohort of Israeli women. Breast Cancer Res Treat 2006;100:201-12.
14. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Risk of breast cancer in a cohort in infertile women. Gynecol Oncol 1996;60:3-7.
15. Terry KL, Willett WC, Rich-Edwards JW, Michels KB. A prospective study of infertility due to ovulatory disorders, ovulation induction, and incidence of breast cancer. Arch Intern Med 2006;166:2484-9.
16. Ricci E, Parazzini F, Negri E, Marsico S, La Vecchia C. Fertility drugs and the risk of breast cancer. Hum Reprod 1999;14:1653-5.
17. Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 2002;17:2209-13.
18. Gauthier E, Paoletti X, Clavel-Chapelon F. Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study. Hum Reprod 2004;19:2216-21.
19. Boyd NF, Rommens JM, Vogt K, et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 2005;6:798-808.
20. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:1159-69.
21. Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 2003;138:168-75.
22. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7:1133-44.
23. Buist DS, Aiello EJ, Miglioretti DL, White E. Mammographic breast density, dense area, and breast area differences by phase in the menstrual cycle. Cancer Epidemiol Biomarkers Prev 2006;15:2303-6.
24. Taplin SH, Mandelson MT, Anderman C, et al. Mammography diffusion and trends in late-stage breast cancer: evaluating outcomes in a population. Cancer Epidemiol Biomarkers Prev 1997;6:625-31.
25. Taplin SH, Ichikawa L, Buist DS, Seger D, White E. Evaluating organized breast cancer screening implementation: the prevention of late-stage disease? Cancer Epidemiol Biomarkers Prev 2004;13:225-34.
26. American College of Radiology. The American College of Radiology Breast Imaging Reporting and Data System (BI-RADS). Virginia: Reston;2003.
27. Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 2001;285:171-6.
28. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in vitro fertilisation. Lancet 1999;354:1586-90.
29. Brinton LA, Scoccia B, Moghissi KS, et al. Breast cancer risk associated with ovulation-stimulating drugs. Hum Reprod 2004;19:2005-13.
30. Dodd GD. American Cancer Society guidelines on screening for breast cancer. An overview. Cancer 1992;69:1885-7.
31. U S. Preventive Services Task Force. Screening for breast cancer: recommendations and rationale. Ann Intern Med 2002;137:344-6.
32. Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe L, Jr. A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update 2000;6:212-24.
33. Sutherland RL, Watts CK, Hall RE, Ruenitz PC. Mechanisms of growth inhibition by nonsteroidal antioestrogens in human breast cancer cells. J Steroid Biochem 1987;27:891-7.
34. Richards JF, Griffith DR. Effect of cis-and trans-clomiphene on mammary gland development in the rat. Fertil Steril 1974;25:74-8.
35. Hecker E, Vegh I, Levy CM, et al. Clinical trial of clomiphene in advanced breast cancer. Eur J Cancer 1974;10:747-9.